LEO Pharma Gains China Psoriasis Access with Enstilar Approval
Event summary
- LEO Pharma secured NMPA approval for Enstilar (calcipotriene/betamethasone dipropionate) to treat plaque psoriasis in China.
- The approval grants access to a new treatment option for an estimated 6.5 million Chinese patients.
- Enstilar, a foam formulation, demonstrated superiority to Daivobet ointment in a Phase 3 clinical trial.
- The launch of Enstilar in China is planned for later in 2026.
The big picture
China represents a significant growth opportunity for dermatology companies, driven by a large patient population and increasing healthcare spending. LEO Pharma's success in China will hinge on navigating the evolving regulatory landscape and competing with established players. This approval reinforces LEO Pharma’s strategy of expanding its global footprint, particularly in high-growth markets.
What we're watching
- Market Penetration
- The speed of Enstilar's adoption in China will depend on physician familiarity and reimbursement policies, potentially impacting LEO Pharma's revenue projections.
- Portfolio Expansion
- LEO Pharma's stated plans for additional dermatology therapies in China will be crucial to assess the long-term strategic value of this approval.
- Competitive Response
- Competitors like Daivobet's manufacturer will likely respond with promotional activities or new product development, potentially eroding Enstilar's market share.
Related topics